Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

OTHER 13INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Conditions

Polycystic Ovary Syndrome 2Anovulation 1

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Chorionic Gonadotropin × Clear all
NCT01653743 2016-01-07

Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women

Merck KGaA, Darmstadt, Germany

Phase 3 Completed
81 enrolled 11 charts

Anovulation, Polycystic Ovary Syndrome

NCT01185704 2014-02-13

ATTAC-PCO

Merck KGaA, Darmstadt, Germany

Phase 3 Completed
136 enrolled 21 charts

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡